VP
NBRV

venBio Partners’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

venBio Partners’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-712
Closed -$619K – 4
2018
Q2 		$619K Sell
712
-7,780
-92% -$8.91M 0.64% 4
2018
Q1 		$10.7M Hold
8,492
– – 6.58% 4
2017
Q4 		$12.7M Buy
+8,492
New +$13.4M 12.6% 2

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

venBio Partners's NBRV Position: Q3 2018 in Review

venBio Partners sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2018, closing a stake of 712 shares — an estimated $619K sold.

venBio Partners first reported a position in NBRV in Q4 2017 and held it in 3 quarters. The position peaked at $12.7M in Q4 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q3 2018.

  • venBio Partners reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2018 after selling out during the quarter.
  • venBio Partners sold 712 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2018, an estimated $619K.
  • venBio Partners first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 3 quarters.
  • venBio Partners's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $12.7M in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2018.

Based on venBio Partners's 13F filing for Q3 2018, filed 14 Nov 2018.